A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology

Klaus Bühler, Olaf G J Naether, Wilma Bilger, Klaus Bühler, Olaf G J Naether, Wilma Bilger

Abstract

Background: Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) both have a role to play in follicular development during the natural menstrual cycle. LH supplementation during controlled ovarian stimulation (COS) for assisted reproductive technology (ART) is used for patients with hypogonadotropic hypogonadism. However, the use of exogenous LH in COS in normogonadotropic women undergoing ART is the subject of debate. The aim of this study was to investigate characteristics of infertile women who received the 2:1 formulation of follitropin alfa and lutropin alfa (indicated for stimulation of follicular development in women with severe LH and FSH deficiency) in German clinical practice.

Methods: A 3-year, multicentre, open-label, observational/non-interventional, post-marketing surveillance study of women (21-45 years) undergoing ART. Primary endpoint: reason for prescribing the 2:1 formulation of follitropin alfa and lutropin alfa. Secondary variables included: COS duration/dose; oocytes retrieved; fertilization; clinical pregnancy; ovarian hyperstimulation syndrome (OHSS).

Results: In total, 2220 cycles were assessed; at least one reason for prescribing the 2:1 formulation was given in 1834/2220 (82.6%) cycles. Most common reasons were: poor ovarian response (POR) (39.4%), low baseline LH (17.8%), and age (13.8%). COS: mean dose of the 2:1 formulation on first day, 183.1/91.5 IU; mean duration, 10.8 days. In 2173/2220 (97.9%) cycles, human chorionic gonadotrophin was administered. Oocyte pick-up (OPU) was attempted in 2108/2220 (95.0%) cycles; mean (standard deviation) 8.0 (5.4) oocytes retrieved/OPU cycle. Fertilization (≥1 oocyte fertilized) rates: in vitro fertilization (IVF), 391/439 (89.1%) cycles; intracytoplasmic sperm injection (ICSI)/IVF + ICSI, 1524/1613 (94.5%) cycles. Clinical pregnancy rate: all cycles, 25.9%; embryo transfer cycles, 31.3%. OHSS: hospitalization for OHSS, 8 (0.36%) cycles, Grade 2, 60 (2.7%), and Grade 3, 1 (0.05%).

Conclusions: In German routine clinical practice, the most common reasons for using the 2:1 formulation of follitropin alfa and lutropin alfa for women undergoing ART were POR, low baseline LH, and age. Severe OHSS incidence was low and similar to that reported previously.

Trial registration: ClinicalTrials.gov NCT01112618.

Figures

Figure 1
Figure 1
The reasons cited by physicians for prescribing the 2:1 formulation of follitropin alfa and lutropin alfa for 1834/2220 assisted reproductive technology (ART) cycles. (a) The number of reported pre-specified reasons (one or more reasons could be given; 1889 reasons were given for 1834 ART cycles); (b) Expansion of the pre-specified answer of ‘other’ (1315 responses of other were given in total; the six reasons cited most frequently are shown). Percentages are based on 1889 reasons. GnRH = gonadotrophin-releasing hormone; LH = luteinizing hormone.

References

    1. Fischer R. Understanding the role of LH: myths and facts. Reprod Biomed Online. 2007;15:468–477. doi: 10.1016/S1472-6483(10)60375-6.
    1. Filicori M, Cognigni GE, Pocognoli P, Ciampaglia W, Bernardi S. Current concepts and novel applications of LH activity in ovarian stimulation. Trends Endocrinol Metab. 2003;14:267–273. doi: 10.1016/S1043-2760(03)00085-7.
    1. Buhler K, Naether O. A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study. Gynecol Endocrinol. 2011;27:650–654. doi: 10.3109/09513590.2010.511014.
    1. European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab. 1998;83:1507–1514.
    1. Hill MJ, Levy G, Levens ED. Does exogenous LH in ovarian stimulation improve assisted reproduction success? an appraisal of the literature. Reprod Biomed Online. 2012;24:261–271. doi: 10.1016/j.rbmo.2011.12.005.
    1. Buhler KF, Fischer R. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case–control study. Gynecol Endocrinol. 2011;28:345–350.
    1. Mochtar MH, van der Veen F, Ziech M, van Wely M. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2007;2:CD005070.
    1. Humaidan P, Bungum M, Bungum L, Yding AC. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online. 2004;8:635–643. doi: 10.1016/S1472-6483(10)61643-4.
    1. Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril. 2011;95:1031–1036. doi: 10.1016/j.fertnstert.2010.10.021.
    1. Ferraretti AP, Gianaroli L, Magli MC, D’Angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril. 2004;82:1521–1526. doi: 10.1016/j.fertnstert.2004.06.041.
    1. Agostinetto R. Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment. Reprod Biol Endocrinol. 2009;7:48. doi: 10.1186/1477-7827-7-48.
    1. Alper M, Meyer R, Dekkers C, Ezcurra D, Schertz J, Kelly E. Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague–Dawley rats. Reprod Biol Endocrinol. 2008;6:31. doi: 10.1186/1477-7827-6-31.
    1. Picard M, Rossier C, Papasouliotis O, Lugan I. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two phase I, randomised, crossover studies. Curr Med Res Opin. 2008;24:1199–1208. doi: 10.1185/030079908X291949.
    1. Pergoveris; follitropin alfa / lutropin alfa: product information (Europe) . Accessed 13 March 2013.
    1. Buhler K, Bals-Pratsch M, Kupka M. the Board of Trustees. D.I.R Annual 2009 - German IVF-Registry e.V. J Reproduktionsmed Endokrinol. 2010;7:470–497.
    1. Pak SJ, Warlich J, Rooij TN van. [RecDate - an IT-solution for the documentation and quality management of reproductive medicine] Zentralbl Gynakol. 2001;123:482–486. doi: 10.1055/s-2001-17250.
    1. Buhler K, Bals-Pratsch M, Blumenauer V, Dahncke W, Felberbaum R, Fiedler K, Gnoth C, Happel L, Krüssel MS, Kupka M, Wendelken M. D.I.R Annual 2010 - German IVF-Registry. J Reproduktionsmed Endokrinol. 2011;8:253–280.
    1. Kupka MS, Bühler K, Dahncke W, Wendelken M, Bals-Pratsch M. Summary of the 2008 Annual Report of the German IVF Registry. J Reproduktionsmed Endokrinol. 2010;7:34–38.
    1. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update. 2002;8:141–154. doi: 10.1093/humupd/8.2.141.
    1. Broekmans FJ, Soules MR, Fauser BC. Ovarian ageing: mechanisms and clinical consequences. Endocr Rev. 2009;30:465–493. doi: 10.1210/er.2009-0006.
    1. König TE, van der Houwen LE, Overbeek A, Hendriks ML, Beutler-Beemsterboer SN, Kuchenbecker WK, Renckens CN, Bernardus RE, Schats R, Homburg R, Hompes PG, Lambalk CB. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod. 2013;28(10):2804–2812. doi: 10.1093/humrep/det266.
    1. Hill MJ, Levens ED, Levy G, Ryan ME, Csokmay JM, DeCherney AH, Whitcomb BW. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril. 2012;97:1108–1114. doi: 10.1016/j.fertnstert.2012.01.130.
    1. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320:1708–1712. doi: 10.1136/bmj.320.7251.1708.
    1. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26:1616–1624. doi: 10.1093/humrep/der092.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit